Literature DB >> 19224990

Persistent West Nile virus associated with a neurological sequela in hamsters identified by motor unit number estimation.

Venkatraman Siddharthan1, Hong Wang, Neil E Motter, Jeffery O Hall, Robert D Skinner, Ramona T Skirpstunas, John D Morrey.   

Abstract

To investigate the hypothesis that neurological sequelae are associated with persistent West Nile virus (WNV) and neuropathology, we developed an electrophysiological motor unit number estimation (MUNE) assay to measure the health of motor neurons temporally in hamsters. The MUNE assay was successful in identifying chronic neuropathology in the spinal cords of infected hamsters. MUNE was suppressed at days 9 to 92 in hamsters injected subcutaneously with WNV, thereby establishing that a long-term neurological sequela does occur in the hamster model. MUNE suppression at day 10 correlated with the loss of neuronal function as indicated by reduced choline acetyltransferase staining (R(2) = 0.91). Between days 10 and 26, some alpha-motor neurons had died, but further neuronal death was not detected beyond day 26. MUNE correlated with disease phenotype, because the lowest MUNE values were detected in paralyzed limbs. Persistent WNV RNA and foci of WNV envelope-positive cells were identified in the central nervous systems of all hamsters tested from 28 to 86 days. WNV-positive staining colocalized with the neuropathology, which suggested that persistent WNV or its products contributed to neuropathogenesis. These results established that persistent WNV product or its proteins cause dysfunction, that WNV is associated with chronic neuropathological lesions, and that this neurological sequela is effectively detected by MUNE. Inasmuch as WNV-infected humans can also experience a poliomyelitis-like disease where motor neurons are damaged, MUNE may also be a sensitive clinical or therapeutic marker for those patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19224990      PMCID: PMC2668437          DOI: 10.1128/JVI.00017-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  Complete genome sequences and phylogenetic analysis of West Nile virus strains isolated from the United States, Europe, and the Middle East.

Authors:  Robert S Lanciotti; Gregory D Ebel; Vincent Deubel; Amy J Kerst; Severine Murri; Richard Meyer; Michael Bowen; Nancy McKinney; William E Morrill; Mary B Crabtree; Laura D Kramer; John T Roehrig
Journal:  Virology       Date:  2002-06-20       Impact factor: 3.616

2.  Randomized controlled trial of strength training in post-polio patients.

Authors:  K Ming Chan; Nasim Amirjani; Mae Sumrain; Anita Clarke; Fay J Strohschein
Journal:  Muscle Nerve       Date:  2003-03       Impact factor: 3.217

3.  Comparison of incremental with multipoint MUNE methods in transgenic ALS mice.

Authors:  Jeremy M Shefner; Merit E Cudkowicz; Robert H Brown
Journal:  Muscle Nerve       Date:  2002-01       Impact factor: 3.217

4.  Caspase 3-dependent cell death of neurons contributes to the pathogenesis of West Nile virus encephalitis.

Authors:  Melanie A Samuel; John D Morrey; Michael S Diamond
Journal:  J Virol       Date:  2006-12-27       Impact factor: 5.103

5.  Nucleic acid sequence-based amplification assays for rapid detection of West Nile and St. Louis encephalitis viruses.

Authors:  R S Lanciotti; A J Kerst
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

6.  Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model.

Authors:  John D Morrey; Venkatraman Siddharthan; Aaron L Olsen; Hong Wang; Justin G Julander; Jeffery O Hall; Hua Li; Jeffrey L Nordstrom; Scott Koenig; Syd Johnson; Michael S Diamond
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191

7.  Histopathologically proven poliomyelitis with quadriplegia and loss of brainstem function due to West Nile virus infection.

Authors:  Shira I Doron; John F Dashe; Lester S Adelman; William F Brown; Barbara G Werner; Susan Hadley
Journal:  Clin Infect Dis       Date:  2003-08-11       Impact factor: 9.079

Review 8.  The long-term outcomes of human West Nile virus infection.

Authors:  James J Sejvar
Journal:  Clin Infect Dis       Date:  2007-05-02       Impact factor: 9.079

9.  Axonal transport mediates West Nile virus entry into the central nervous system and induces acute flaccid paralysis.

Authors:  Melanie A Samuel; Hong Wang; Venkatraman Siddharthan; John D Morrey; Michael S Diamond
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-15       Impact factor: 11.205

10.  Acute flaccid paralysis and West Nile virus infection.

Authors:  James J Sejvar; A Arturo Leis; Dobrivoje S Stokic; Jay A Van Gerpen; Anthony A Marfin; Risa Webb; Maryam B Haddad; Bruce C Tierney; Sally A Slavinski; Jo Lynn Polk; Victor Dostrow; Michael Winkelmann; Lyle R Petersen
Journal:  Emerg Infect Dis       Date:  2003-07       Impact factor: 6.883

View more
  27 in total

Review 1.  The contribution of rodent models to the pathological assessment of flaviviral infections of the central nervous system.

Authors:  David C Clark; Aaron C Brault; Elizabeth Hunsperger
Journal:  Arch Virol       Date:  2012-05-17       Impact factor: 2.574

2.  Evaluation of prolonged fatigue post-West Nile virus infection and association of fatigue with elevated antiviral and proinflammatory cytokines.

Authors:  Melissa N Garcia; Anne M Hause; Christopher M Walker; Jordan S Orange; Rodrigo Hasbun; Kristy O Murray
Journal:  Viral Immunol       Date:  2014-07-25       Impact factor: 2.257

3.  Visualization of West Nile Virus in Urine Sediment using Electron Microscopy and Immunogold up to Nine Years Postinfection.

Authors:  Kristy O Murray; Steven Kolodziej; Shannon E Ronca; Rodion Gorchakov; Patricia Navarro; Melissa S Nolan; Amber Podoll; Kevin Finkel; Sreedhar Mandayam
Journal:  Am J Trop Med Hyg       Date:  2017-10-19       Impact factor: 2.345

4.  West nile virus RNA not detected in urine of 40 people tested 6 years after acute West Nile virus disease.

Authors:  Katherine B Gibney; Robert S Lanciotti; James J Sejvar; C Thomas Nugent; Jeffrey M Linnen; Mark J Delorey; Jennifer A Lehman; Erin N Boswell; J Erin Staples; Marc Fischer
Journal:  J Infect Dis       Date:  2010-12-15       Impact factor: 5.226

Review 5.  Neurological approaches for investigating West Nile virus disease and its treatment in rodents.

Authors:  John D Morrey; Venkatraman Siddharthan; Hong Wang
Journal:  Antiviral Res       Date:  2013-09-19       Impact factor: 5.970

6.  Treatment of spatial memory impairment in hamsters infected with West Nile virus using a humanized monoclonal antibody MGAWN1.

Authors:  Cynthia A Smeraski; Venkatraman Siddharthan; John D Morrey
Journal:  Antiviral Res       Date:  2011-04-30       Impact factor: 5.970

7.  Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model.

Authors:  Justin G Julander; Venkatraman Siddharthan; Joe Evans; Ray Taylor; Kelsey Tolbert; Chad Apuli; Jason Stewart; Preston Collins; Makda Gebre; Skot Neilson; Arnaud Van Wettere; Young-Min Lee; William P Sheridan; John D Morrey; Y S Babu
Journal:  Antiviral Res       Date:  2016-11-10       Impact factor: 5.970

Review 8.  West Nile Virus: biology, transmission, and human infection.

Authors:  Tonya M Colpitts; Michael J Conway; Ruth R Montgomery; Erol Fikrig
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

9.  Persistent infection with West Nile virus years after initial infection.

Authors:  Kristy Murray; Christopher Walker; Emily Herrington; Jessica A Lewis; Joseph McCormick; David W C Beasley; Robert B Tesh; Susan Fisher-Hoch
Journal:  J Infect Dis       Date:  2010-01-01       Impact factor: 5.226

10.  West nile virus: characteristics of an african virus adapting to the third millennium world.

Authors:  Marina Monini; Emiliana Falcone; Luca Busani; Roberto Romi; Franco Maria Ruggeri
Journal:  Open Virol J       Date:  2010-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.